These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2190629)

  • 1. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.
    Brunel P; Lecaillon JB; Guyene TT; Imhof P; Ménard J
    Br J Clin Pharmacol; 1990 May; 29(5):503-9. PubMed ID: 2190629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of acetylation phenotype on the pharmacokinetics and pharmacodynamics data of cadralazine in normotensive subjects].
    Brunel P; Lecaillon JB; Imhof P; Menard J
    Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1257-60. PubMed ID: 2510657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.
    Marichal JF; Brunel P; Lecaillon JB; Godbillon J; Faller B; Brignon P; Ménard J
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):213-20. PubMed ID: 1490491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cadralazine in hypertensive patients.
    Leonetti G; Parini J; Visconti M; Gradnik R
    Eur J Drug Metab Pharmacokinet; 1988; 13(4):295-300. PubMed ID: 3243325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs.
    Higashio T; Tsuji Y; Nakao K; Sakaguchi S; Tanaka M
    Arzneimittelforschung; 1988 Mar; 38(3):350-8. PubMed ID: 3382459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs.
    Dorigotti L; Ferni G; Lombroso M; Semeraro C
    Arzneimittelforschung; 1984; 34(9):984-7. PubMed ID: 6542375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
    Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
    Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
    Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
    Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs.
    Yukimura T; Miura K; Tanaka M; Higashio T; Sakaguchi S; Kuroda K; Yamamoto K
    Arzneimittelforschung; 1988 Jan; 38(1):25-8. PubMed ID: 3284531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.
    Catalano M; Parini J; Libretti A
    Eur J Clin Pharmacol; 1983; 24(2):157-61. PubMed ID: 6840161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic effects of single-dose felodipine in normal man.
    Agner E; Rehling M; Trap-Jensen J
    Drugs; 1985; 29 Suppl 2():36-40. PubMed ID: 3987549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemorheologic effects of vasodilation in essential hypertension.
    Wysocki M; Andersson OK; Persson B; Bagge U; Braide M
    Angiology; 1996 Sep; 47(9):869-78. PubMed ID: 8810653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal function studies with cadralazine in conscious dogs: a comparison with hydralazine.
    Ferni G; Bonardi G; Lombroso M; Semeraro C; Dorigotti L
    Pharmacol Res; 1989; 21(2):211-22. PubMed ID: 2664751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive activity of cadralazine in experimental hypertensive rats.
    Takeyama K; Ikeno A; Minato H; Fukuya F; Nishimura S; Hosoki K; Kadokawa T
    Arch Int Pharmacodyn Ther; 1988; 291():163-74. PubMed ID: 3365060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
    Pålsson L; Weiner L; Englund G; Henning M
    Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
    Buoninconti R; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
    Lecaillon JB; Dubois JP; Darragon T; Motolese M; Racine A; Ducret F; Grouberman D; Cordonnier D; Chanard J; Glorioso M
    Ther Drug Monit; 1991 Mar; 13(2):103-8. PubMed ID: 2053115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    McTavish D; Young RA; Clissold SP
    Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.